Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -11.89% is 50% above its 5-year average of -23.90%, near the high end of its 5-year range (-131.03%–-0.12%).
13.46% below its 12-month average of -10.48%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-06-30): -0.12%.
EBITDA MARGIN
-11.89%
EBITDA MARGIN AVG TTM
-10.48%
EBITDA MARGIN AVG 3Y
-22.77%
EBITDA MARGIN AVG 5Y
-23.90%
EBITDA MARGIN AVG 10Y
-37.99%
EBITDA MARGIN AVG 15Y
-40.00%
EBITDA MARGIN AVG 20Y
-54.11%
CURRENT VS TTM AVG
-13.46%
CURRENT VS 3Y AVG
+47.77%
CURRENT VS 5Y AVG
+50.24%
CURRENT VS 10Y AVG
+68.70%
CURRENT VS 15Y AVG
+70.27%
CURRENT VS 20Y AVG
+78.03%
Sonoma Pharmaceuticals, Inc.
Market Cap
$5.79M
EBITDA Margin
-11.89%
TTM Avg
-10.48%
3Y Avg
-22.77%
5Y Avg
-23.90%
Market Cap
$5.86M
EBITDA Margin
-314.07%
TTM Avg
-394.57%
3Y Avg
-554.22%
5Y Avg
-637.29%
Market Cap
$5.70M
EBITDA Margin
-23296.89%
TTM Avg
-13717.94%
3Y Avg
-7355.60%
5Y Avg
-5953.70%
Market Cap
$5.94M
EBITDA Margin
-3649.83%
TTM Avg
-7184.74%
3Y Avg
-3660.35%
5Y Avg
-2451.26%
Market Cap
$5.89M
EBITDA Margin
-41051.94%
TTM Avg
-32118.88%
3Y Avg
-145781.05%
5Y Avg
-130042.11%
Market Cap
$5.89M
EBITDA Margin
-417.17%
TTM Avg
-417.17%
3Y Avg
-417.17%
5Y Avg
-417.17%
Market Cap
$5.58M
EBITDA Margin
-9081.41%
TTM Avg
-6199.48%
3Y Avg
-3862.58%
5Y Avg
-3269.64%
Market Cap
$5.34M
EBITDA Margin
-5685.74%
TTM Avg
-22429.68%
3Y Avg
-11536.25%
5Y Avg
-7742.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | $5.79M | -11.89% | -10.48% | -22.77% | -23.90% |
| Lucyd, Inc (LUCY)vs › | $5.86M | -314.07% | -394.57% | -554.22% | -637.29% |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -23296.89% | -13717.94% | -7355.60% | -5953.70% |
| Scienture Holdings, Inc. (SCNX)vs › | $5.94M | -3649.83% | -7184.74% | -3660.35% | -2451.26% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.89M | -41051.94% | -32118.88% | -145781.05% | -130042.11% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.89M | -417.17% | -417.17% | -417.17% | -417.17% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.58M | -9081.41% | -6199.48% | -3862.58% | -3269.64% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | -5685.74% | -22429.68% | -11536.25% | -7742.59% |
| Femasys Inc. (FEMY)vs › | $6.28M | -729.87% | -884.05% | -981.20% | -851.95% |
Gross Margin
38.9%
EBITDA Margin
-11.9%
Operating Margin
-6.4%
Net Margin
-10.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -0.12% |
| 2026-03-31 | -5.72% |
| 2025-12-31 | -14.81% |
| 2025-09-30 | -5.37% |
| 2025-06-30 | -26.38% |
| 2025-03-31 | -16.65% |
| 2024-12-31 | -28.00% |
| 2024-09-30 | -22.77% |
| 2024-06-30 | -33.44% |
| 2024-03-31 | -39.78% |
| 2023-12-31 | -25.46% |
| 2023-09-30 | -42.59% |
| 2023-06-30 | -34.87% |
| 2023-03-31 | -36.93% |
| 2022-12-31 | -61.21% |
| 2022-09-30 | -21.10% |
| 2022-06-30 | -20.69% |
| 2022-03-31 | -131.03% |
| 2021-12-31 | -31.74% |
| 2021-09-30 | -24.36% |
| 2021-06-30 | -23.24% |
| 2021-03-31 | -128.60% |
| 2020-12-31 | -1.18% |
| 2020-09-30 | 3.87% |
| 2020-06-30 | -10.61% |
| 2020-03-31 | -72.45% |
| 2019-12-31 | -23.66% |
| 2019-09-30 | -25.79% |
| 2019-06-30 | -37.71% |
| 2019-03-31 | -59.29% |
| 2018-12-31 | -42.44% |
| 2018-09-30 | -51.33% |
| 2018-06-30 | -78.53% |
| 2018-03-31 | -126.54% |
| 2017-12-31 | -63.49% |
| 2017-09-30 | -63.01% |
| 2017-06-30 | -85.37% |
| 2017-03-31 | -70.54% |
| 2016-12-31 | -104.28% |
| 2016-09-30 | -104.68% |
| 2016-06-30 | -130.71% |
| 2016-03-31 | -79.24% |
| 2015-12-31 | -166.29% |
| 2015-09-30 | -44.35% |
| 2015-06-30 | -61.11% |
| 2015-03-31 | -39.97% |
| 2014-12-31 | -57.74% |
| 2014-09-30 | -46.17% |
| 2014-06-30 | -42.75% |
| 2014-03-31 | -69.84% |
| 2013-12-31 | -44.67% |
| 2013-09-30 | -29.35% |
| 2013-06-30 | -31.47% |
| 2013-03-31 | -39.31% |
| 2012-12-31 | -17.49% |
| 2012-09-30 | -16.66% |
| 2012-06-30 | -10.42% |
| 2012-03-31 | -41.30% |
| 2011-12-31 | -81.54% |
| 2011-09-30 | -14.93% |
| 2011-06-30 | -65.82% |
| 2011-03-31 | -46.96% |
| 2010-12-31 | -85.65% |
| 2010-09-30 | -63.06% |
| 2010-06-30 | -101.63% |
| 2010-03-31 | -60.66% |
| 2009-12-31 | -118.41% |
| 2009-09-30 | -128.05% |
| 2009-06-30 | -117.92% |
| 2009-03-31 | -142.17% |
| 2008-12-31 | -243.00% |
| 2008-09-30 | -434.30% |
| 2008-06-30 | -398.51% |
| 2008-03-31 | -603.02% |
| 2007-12-31 | -503.00% |
| 2007-09-30 | -561.92% |
| 2007-06-30 | -606.12% |
| 2007-03-31 | -481.58% |
| 2006-12-31 | -470.25% |
| 2006-09-30 | 416.85% |
| 2006-06-30 | 113.73% |
| 2006-03-31 | -3020.51% |
| 2005-12-31 | 100.00% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | -5111.80% |
| 2004-12-31 | 100.00% |
| 2004-09-30 | 100.00% |
| 2004-06-30 | 100.00% |
